Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABY-029 Fluorescence in Head and Neck Squamous Cell Carcinoma
NCT07279116Phase 1Not yet recruiting
- Sponsor
- Dartmouth Health
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Peptides
01
Overview
Phase 1, open-label trial of ABY-029 in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Dartmouth Health. Primary endpoints: Adverse events related to ABY-029 at 1 month and Diagnostic accuracy of measured ABY-029 fluorescence ex-vivo in surgical specimens up to 3 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ABY-029
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07279116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07279116.